Compare CLDT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDT | CHRS |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.9M | 296.8M |
| IPO Year | N/A | 2014 |
| Metric | CLDT | CHRS |
|---|---|---|
| Price | $8.61 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $11.00 | $5.51 |
| AVG Volume (30 Days) | 227.7K | ★ 982.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | N/A |
| Revenue This Year | $2.94 | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $610.21 | ★ $1.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.08 | $0.72 |
| 52 Week High | $8.93 | $2.62 |
| Indicator | CLDT | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 54.62 |
| Support Level | $7.58 | $1.55 |
| Resistance Level | N/A | $1.89 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 57.62 | 56.79 |
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.